Details for Patent: 12,016,856

Which drugs does patent 12,016,856 protect, and when does it expire?

Patent 12,016,856 protects IBSRELA and XPHOZAH and is included in two NDAs.

This patent has thirty-seven patent family members in twenty-one countries.

Recent additions to Drugs Protected by US Patent 12,016,856

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET	211801	Sep 12, 2019	RX	Yes		Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET	213931	Oct 17, 2023	DISCN	Yes		Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET	213931	Oct 17, 2023	RX	Yes		Y	Y

Drugs Protected by US Patent 12,016,856

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-001	Oct 17, 2023		DISCN	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-002	Oct 17, 2023		RX	Yes	No			Y	Y
Ardelyx Inc	XPHOZAH	tenapanor hydrochloride	TABLET;ORAL	213931-003	Oct 17, 2023		RX	Yes	Yes			Y	Y

International Family Members for US Patent 12,016,856

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009334511
Brazil	PI0923861
Canada	2748607
China	102333759